Hypertension:高血压和肥胖或为肾癌风险因子

2014-03-30 lostree5544 丁香园

  2014年3月17日匹兹堡大学的McTigue博士等在Hypertension发表一篇文章,提出血压的升高和BMI指数可作为肾癌的预测因子。McTigue博士以及同事对美国两大研究中心的群体进行研究,分别为女性健康中心临床试验和观测研究(156774名女性)和多危险干预试验(353340名男性),随访15-25年。   通过对女性健康中心的人群分析发现,相比收缩压≤120mmHg,收缩

  2014年3月17日匹兹堡大学的McTigue博士等在Hypertension发表一篇文章,提出血压的升高和BMI指数可作为肾癌的预测因子。McTigue博士以及同事对美国两大研究中心的群体进行研究,分别为女性健康中心临床试验和观测研究(156774名女性)和多危险干预试验(353340名男性),随访15-25年。

  通过对女性健康中心的人群分析发现,相比收缩压≤120mmHg,收缩压≥140mmHg人群肾癌的发病率上升。BMI研究中也出现类似的情况,尽管该趋势只在BMI>30kg/m2的人群中出现。

  多危险干预试验组中,随访过程中0.26%的男性死于肾癌患者,随着收缩压的升高(即使是在正常血压范围内),其危险性逐渐上升。相比血压 <120mm Hg的人群,血压为 120 -129 mm Hg的人群发病风险率为1.29,血压≥160mm Hg发病风险率则为1.87。

  此外,通过校正发现,吸烟人群肾癌的发病风险为1.75。在肾癌的发病风险上,吸烟与收缩压在肾癌的发病率上具有协同作用。

  研究人员提出,肥胖引发肾小球过滤升高,增加肾血流量,这导致了肾脏损伤和致癌的易感性。此外,高血压并发慢性肾功能缺氧(缺氧诱导因子上调)也可能导致肿瘤的发生。

  另外,肥胖和高血压与氧化应激和脂质过氧化相关,该现象可能在肾癌致病中起重要作用。同时,肥胖引起的胰岛素和胰岛素样生长因子 I 水平上升,增加了肿瘤的发生风险。当然,不能排除环境因素可能导致的肾脏损伤(导致肾癌发生)和血压的升高。

  研究对该研究存在的局限性进行了说明,比例随访的时间还太短,未能检测到肿瘤的发生,也未能观察到亚型肾癌的发展;另外,白种男性和女性人群中癌症发病率较高,这对于其他种族人群的研究造成了一定的障碍。

  虽然目前高血压和肥胖与肾癌相关性的病理生理学机制仍不明确,也不能将两者与肾癌的关系直接定义为因果关系,但是该研究为肾癌的危险因素提供了一定的补充,同时为降低肾癌的发病风险提出了新的假说,比如是否通过特定药物降低血压是否可以降低肾癌的发病风险?

原始出处:

Sanfilippo KM, McTigue KM, Fidler CJ, Neaton JD, Chang Y, Fried LF, Liu S, Kuller LH.Hypertension and Obesity and the Risk of Kidney Cancer in 2 Large Cohorts of US Men and Women.Hypertension. 2014 Mar 17.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038485, encodeId=d79f203848597, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 30 11:17:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725583, encodeId=6b561e2558339, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 13 17:17:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061426, encodeId=b845206142608, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Feb 03 17:17:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501039, encodeId=0c7915010392f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529248, encodeId=e14b152924852, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038485, encodeId=d79f203848597, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 30 11:17:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725583, encodeId=6b561e2558339, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 13 17:17:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061426, encodeId=b845206142608, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Feb 03 17:17:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501039, encodeId=0c7915010392f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529248, encodeId=e14b152924852, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=)]
    2014-11-13 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038485, encodeId=d79f203848597, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 30 11:17:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725583, encodeId=6b561e2558339, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 13 17:17:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061426, encodeId=b845206142608, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Feb 03 17:17:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501039, encodeId=0c7915010392f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529248, encodeId=e14b152924852, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=)]
    2015-02-03 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038485, encodeId=d79f203848597, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 30 11:17:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725583, encodeId=6b561e2558339, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 13 17:17:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061426, encodeId=b845206142608, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Feb 03 17:17:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501039, encodeId=0c7915010392f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529248, encodeId=e14b152924852, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038485, encodeId=d79f203848597, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 30 11:17:00 CST 2014, time=2014-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725583, encodeId=6b561e2558339, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 13 17:17:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061426, encodeId=b845206142608, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Feb 03 17:17:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501039, encodeId=0c7915010392f, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529248, encodeId=e14b152924852, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Tue Apr 01 11:17:00 CST 2014, time=2014-04-01, status=1, ipAttribution=)]

相关资讯

Nature Genetics:数种肾癌变异基因被发现

  日本研究人员最新报告说,他们已经发现并彻底研究了与肾癌有关的数种基因变异,这有助于开发治疗肾癌的新药和疗法。  京都大学和东京大学等机构的研究人员25日在《自然·遗传学》期刊网络版上报告说,他们对100多名透明细胞性肾癌患者进行研究,发现一种名为VHL的基因出现变异的频率非常高,被认为是导致肾癌的主要原因之一。  研究人员还通过对比研究患者的癌细胞染色体组发现,92%的患者VHL基因出现变异。

一例孤肾25颗肿瘤患者的成功切除

  5月15日,中南大学湘雅医院泌尿外科主任齐琳 “快刀”为1例年过半百并患有罕见中枢神经系统(CNS)血管母细胞瘤合并肾癌(VHL综合征)的女性患者完整切除了孤肾上的25颗肿瘤,同时最大限度地保护了患肾功能。   6年前,患者因右肾肿瘤在当地医院接受了右肾根治性切除术。在1个月前,患者随诊时被告知左肾及左肾上腺出现多发占位性病变。于是患者慕名到湘雅医院就诊。齐琳教授接诊后

罗氏旗下阿瓦斯丁能延长晚期宫颈癌患者生存期

罗氏旗下阿瓦斯丁在一项后期临床试验中被加到化疗中时,能有助于延长晚期宫颈癌妇女的生存期,这可能为这款年销售额达几十亿美元药物增加另一适应症铺平了道路。研究人员说,这标志着第一项研究证实这款阻断肿瘤血管形成的药物能够延长患有妇科癌症妇女的生存期。 在这项有452名宫颈癌已经扩散或复发患者参与的临床试验中,那些接受阿瓦斯丁加化疗治疗的患者平均生存了17个月。而那些只接受化疗治疗的患者平均总生存期为1

Hypertension:高血压和肥胖或为肾癌危险因子

2014年3月17日匹兹堡大学的McTigue博士等在Hypertension发表一篇文章,提出血压的升高和BMI指数可作为肾癌的预测因子。McTigue博士以及同事对美国两大研究中心的群体进行研究,分别为女性健康中心临床试验和观测研究(156774名女性)和多危险干预试验(353340名男性),随访15-25年。【原文下载】 通过对女性健康中心的人群分析发现,相比收

ASCO-GU 2014:肾癌研究与治疗的新进展

2014年美国临床肿瘤学会生殖泌尿肿瘤研讨会(2014ASCO-GU)近日在旧金山召开。本次研讨会涉及泌尿生殖系统各部位的多项研究,其中与肾癌相关的亮点主要集中在基因研究、新的靶向治疗药物及预后模型的建立等多方面,尤其是有关较难处理的转移性肾癌(mRCC)研究占了很大比重。下面由四川大学华西医院的魏强教授结合2014ASCO-GU的相关内容总结概述肾癌基因研究与治疗的最新进展。 基因研究

Cancer Cell:低氧下核蛋白SPOP过表达和错误定位可能是肾癌发病关键机制

近日,中国科学院北京基因组研究所基因组学与信息重点实验室刘江课题组与芝加哥大学的研究人员合作,在肾癌发病机制的研究中取得新进展,揭示在低氧的生理条件下,核蛋白SPOP(speckle-type POZ protein) 的过表达和错误定位是引发肾癌产生的核心因素。相关学术论文SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub